Arrowgrass Capital Partners (US)’s Teva Pharmaceuticals TEVA Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-885,401	Closed	-$16.8M	–	433
2017 Q4	$16.8M	Buy	885,401 +36,489	+4%	+$549K	0.16%	153
2017 Q3	$14.9M	Buy	848,912 +439,509	+107%	+$9.89M	0.11%	224
2017 Q2	$13.6M	Buy	409,403 +8,195	+2%	+$254K	0.1%	248
2017 Q1	$12.9M	Buy	+401,208	New	+$13.7M	0.13%	207
2016 Q2	–	Sell	-100,000	Closed	-$5.35M	–	445
2016 Q1	$5.35M	Buy	+100,000	New	+$5.87M	0.06%	182

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s TEVA Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 885,401 shares — an estimated $16.8M sold.

Arrowgrass Capital Partners (US) first reported a position in TEVA in Q1 2016 and held it in 5 quarters. The position peaked at $16.8M in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Arrowgrass Capital Partners (US) reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 885,401 Teva Pharmaceuticals shares in Q1 2018, an estimated $16.8M.
Arrowgrass Capital Partners (US) first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 5 quarters.
Arrowgrass Capital Partners (US)'s Teva Pharmaceuticals position peaked at $16.8M in Q4 2017.
506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.